Vaxcell-Bio Therapeutics Co., Ltd. (323990.KQ)
KRW 10440.0
(-2.61%)
KRW 10440.0
(-2.61%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -9.42 Billion | -6.04 Billion | -4.66 Billion | -3.3 Billion | -3.58 Billion |
| Net Income | -10.27 Billion | -6.82 Billion | -4.76 Billion | -3.98 Billion | -1.25 Billion |
| Depreciation & Amortization | 399.68 Million | 311.34 Million | 257.24 Million | 185.31 Million | 184.72 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 181.64 Million | 38.21 Million | 46.92 Million | 132.02 Million | 100.62 Million |
| Change in working capital | -233.03 Million | -282.78 Million | -553.84 Million | -171.63 Million | -683.71 Million |
| Other non-cash items | -703.38 Million | 156.81 Thousand | 88.81 Million | 286.57 Million | -1.93 Billion |
| Investing Cash Flow | -51.78 Billion | 4.33 Billion | -3.23 Billion | -20.04 Billion | 2.07 Billion |
| Investments in PPE | -198.5 Million | -290.2 Million | -2.22 Billion | -31.93 Million | -821.9 Million |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -92.3 Billion | -23 Billion | -15.3 Billion | -38.6 Billion | - |
| Sales/Maturities of investments | 41.3 Billion | 28 Billion | 14.3 Billion | 18.6 Billion | - |
| Other Investing Activities | -590.64 Million | -373.98 Million | -9 Million | -17.41 Million | 2.89 Billion |
| Financing Cash Flow | 69.86 Billion | -207.84 Million | 304.74 Million | 29.18 Billion | 1.14 Billion |
| Debt repayment | -216.65 Million | -207.84 Million | -205.82 Million | -185.74 Million | -154.97 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -532.69 Million | - | - | - | - |
| Common Stock Issuance | 71.78 Billion | - | 597.37 Million | 29.36 Billion | 1.29 Billion |
| Other Financing Activities | -1.17 Billion | - | -86.79 Million | 29.36 Billion | 1.29 Billion |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | -96.73 Million | - | - | - | - |
| Other working capital | -136.3 Million | -282.78 Million | -553.84 Million | -171.63 Million | -683.71 Million |
| Cash at beginning of period | 389.66 Million | 2.3 Billion | 9.9 Billion | 4.07 Billion | 4.44 Billion |
| Cash at end of period | 9.04 Billion | 389.66 Million | 2.3 Billion | 9.9 Billion | 4.07 Billion |
| Capital Expenditure | -198.5 Million | -290.2 Million | -2.22 Billion | -31.93 Million | -821.9 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 8.65 Billion | -1.91 Billion | -7.59 Billion | 5.82 Billion | -372.04 Million |
| Free Cash Flow | -9.62 Billion | -6.33 Billion | -6.88 Billion | -3.33 Billion | -4.41 Billion |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.45 Billion | -10.27 Billion | -2.72 Billion | -2.81 Billion | -2.49 Billion | -2.24 Billion |
| Depreciation & Amortization | 158.87 Million | 399.68 Million | 154.17 Million | 83.59 Million | 81.18 Million | 80.72 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 58.66 Million | 181.64 Million | 20.64 Million | 64.37 Million | 63.67 Million | 32.95 Million |
| Change in working capital | -683.16 Million | -233.03 Million | 240.67 Million | -364.91 Million | 62.58 Million | -171.37 Million |
| Other non-cash items | -652.47 Million | -703.38 Million | -409.53 Million | -84.21 Million | -78.53 Million | -131.11 Million |
| Investing Cash Flow | -4.25 Billion | -51.78 Billion | -59.39 Billion | 2.67 Billion | 1.96 Billion | 2.96 Billion |
| Investments in PPE | -799.6 Million | -198.5 Million | -128.58 Million | -3 Million | -32.04 Million | -34.87 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -6.86 Billion | -92.3 Billion | -79 Billion | -3.3 Billion | -5 Billion | -5 Billion |
| Sales/Maturities of investments | 3.45 Billion | 41.3 Billion | 19.99 Billion | 6.3 Billion | 7 Billion | 8 Billion |
| Other Investing Activities | -43.27 Million | -590.64 Million | -263.64 Million | -322 Million | 1.99 Billion | 2.99 Billion |
| Financing Cash Flow | -82.25 Million | 69.86 Billion | 69.97 Billion | -35.96 Million | -36.26 Million | -35.66 Million |
| Debt repayment | -82.25 Million | -216.65 Million | -108.76 Million | -35.96 Million | -36.26 Million | -35.66 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -532.69 Million | -532.69 Million | - | - | - |
| Common Stock Issuance | - | 71.78 Billion | - | - | - | - |
| Other Financing Activities | -82.25 Million | -1.17 Billion | 70.61 Billion | - | - | - |
| Accounts receivables | -1.72 Million | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -986.56 Thousand | -96.73 Million | -96.73 Million | - | - | - |
| Other working capital | -680.45 Million | -136.3 Million | 337.4 Million | -364.91 Million | 62.58 Million | -171.37 Million |
| Cash at beginning of period | 9.04 Billion | 389.66 Million | 476.43 Million | 793.25 Million | 1.01 Billion | 389.66 Million |
| Cash at end of period | 1.18 Billion | 9.04 Billion | 9.04 Billion | 476.43 Million | 793.25 Million | 1.01 Billion |
| Capital Expenditure | -799.6 Million | -198.5 Million | -128.58 Million | -3 Million | -32.04 Million | -34.87 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -7.85 Billion | 8.65 Billion | 8.56 Billion | -316.81 Million | -220.51 Million | 624.1 Million |
| Free Cash Flow | -4.32 Billion | -9.62 Billion | -2.14 Billion | -2.95 Billion | -2.17 Billion | -2.34 Billion |
199800
EFGSF
1750
SWADPOL
MOHCF
ALKKO